EE03026B1 - Asendatud salitsüülhapped, meetod nende valmistamiseks ja nende kasutamine - Google Patents

Asendatud salitsüülhapped, meetod nende valmistamiseks ja nende kasutamine

Info

Publication number
EE03026B1
EE03026B1 EE9400111A EE9400111A EE03026B1 EE 03026 B1 EE03026 B1 EE 03026B1 EE 9400111 A EE9400111 A EE 9400111A EE 9400111 A EE9400111 A EE 9400111A EE 03026 B1 EE03026 B1 EE 03026B1
Authority
EE
Estonia
Prior art keywords
compound
preparation
salicylic acids
substituted salicylic
het
Prior art date
Application number
EE9400111A
Other languages
English (en)
Estonian (et)
Inventor
Hubert Agback Karl
Ahrgren Leif
Thomas Berglindh O.
Haraldsson Martin
Olsson Lars-Inge
Smedeg�rd G�ran
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Publication of EE03026B1 publication Critical patent/EE03026B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C07D261/16—Benzene-sulfonamido isoxazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
EE9400111A 1991-11-18 1994-11-02 Asendatud salitsüülhapped, meetod nende valmistamiseks ja nende kasutamine EE03026B1 (et)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9103397A SE9103397D0 (sv) 1991-11-18 1991-11-18 Nya substituerade salicylsyror

Publications (1)

Publication Number Publication Date
EE03026B1 true EE03026B1 (et) 1997-08-15

Family

ID=20384352

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9400111A EE03026B1 (et) 1991-11-18 1994-11-02 Asendatud salitsüülhapped, meetod nende valmistamiseks ja nende kasutamine

Country Status (29)

Country Link
US (3) US5302718A (lt)
EP (1) EP0613468B1 (lt)
JP (1) JP3259915B2 (lt)
KR (1) KR100253748B1 (lt)
AT (1) ATE194597T1 (lt)
AU (1) AU668528B2 (lt)
CA (1) CA2123697C (lt)
DE (1) DE69231252T2 (lt)
DK (1) DK0613468T3 (lt)
EE (1) EE03026B1 (lt)
ES (1) ES2149780T3 (lt)
FI (1) FI106857B (lt)
GR (1) GR3034585T3 (lt)
HU (2) HU221476B (lt)
IL (1) IL103665A (lt)
LT (1) LT3182B (lt)
LV (1) LV10246B (lt)
MX (1) MX9206647A (lt)
MY (1) MY130169A (lt)
NO (1) NO300805B1 (lt)
NZ (1) NZ244998A (lt)
PT (1) PT101068B (lt)
RU (1) RU2124501C1 (lt)
SE (1) SE9103397D0 (lt)
SK (1) SK282080B6 (lt)
TW (1) TW304944B (lt)
UA (1) UA42869C2 (lt)
WO (1) WO1993010094A1 (lt)
ZA (1) ZA928864B (lt)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514696A (en) * 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
GB9310095D0 (en) * 1993-05-17 1993-06-30 Zeneca Ltd Therapeutic compounds
US5965732A (en) * 1993-08-30 1999-10-12 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
US5405842A (en) * 1994-01-28 1995-04-11 Silverman; Bernard A. Treatment of steroid dependent asthmatics
GB9504854D0 (en) * 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
US6028052A (en) 1995-09-18 2000-02-22 Ligand Pharmaceuticals Incorporated Treating NIDDM with RXR agonists
JPH09124620A (ja) 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
EP0904077A4 (en) 1996-02-20 1999-12-22 Bristol Myers Squibb Co PROCESSES FOR THE PRODUCTION OF BIPHENYL ISOXAZOLE SULFAMIDES
US5856507A (en) * 1997-01-21 1999-01-05 Bristol-Myers Squibb Co. Methods for the preparation of biphenyl isoxazole sulfonamides
US5939446A (en) * 1996-04-09 1999-08-17 Bristol-Myers Squibb Co. Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
JP3814742B2 (ja) * 1996-10-18 2006-08-30 イハラケミカル工業株式会社 ４−フルオロサリチル酸類
WO1998033781A1 (en) * 1997-01-30 1998-08-06 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
GB9804648D0 (en) 1998-03-06 1998-04-29 Zeneca Ltd Chemical compounds
GB9805520D0 (en) * 1998-03-17 1998-05-13 Zeneca Ltd Chemical compounds
GB9811427D0 (en) 1998-05-29 1998-07-22 Zeneca Ltd Chemical compounds
CA2334545A1 (en) 1998-06-12 1999-12-16 Ligand Pharmaceuticals Incorporated Treatment of anti-estrogen resistant breast cancer using rxr modulators
IL144708A0 (en) 1999-03-19 2002-06-30 Bristol Myers Squibb Co Methods for the preparation of biphenyl isoxazole sulfonamide derivatives
MXPA02002319A (es) 1999-09-04 2002-07-30 Astrazeneca Ab Derivados 2-hidroxi-2-metil-3,3,3-trifluoropropanamida con n-fenilo susbtituido que elevan la actividad de la deshidrogenasa de piruvato.
ES2273725T3 (es) 1999-09-04 2007-05-16 Astrazeneca Ab Derivados de hidroxiacetamidobencenosulfonamida.
JP2003508509A (ja) 1999-09-04 2003-03-04 アストラゼネカ アクチボラグ ピルビン酸デヒドロゲナーゼの阻害剤としてのアミド
CA2307278A1 (en) * 2000-04-28 2001-10-28 University Of British Columbia Use of n-heterocyclic substituted salicylic acids for inhibition of cellular uptake of cystine
DE60115414D1 (de) * 2000-04-28 2006-01-05 Univ British Columbia N-heterosubstituierten salicylaten zur behandlung von krebs
US6639082B2 (en) 2000-10-17 2003-10-28 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
KR100360342B1 (ko) * 2002-04-19 2002-11-13 박계정 밸런스 머신의 언밸런스 수정위치 및 수정량의 자동 보상방법
EP1661889A4 (en) * 2003-09-05 2009-08-05 Ono Pharmaceutical Co ANTAGONIST OF THE CHEMOKINE RECEPTOR AND ITS USE FOR MEDICAL PURPOSES
AP2006003633A0 (en) * 2003-12-19 2006-06-30 Pfizer Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-BETA-hydroxysteroid dehydrogenase type 1 (11-BETA-HSD-1) for the treatment of diabetes and obesity
BRPI0512915A (pt) * 2004-06-29 2008-04-15 Warner Lambert Co terapias de combinação utilizando inibidores benzamida do receptor p2x7
GB2421947A (en) * 2005-01-07 2006-07-12 Univ Southampton Sulphonamide compounds for use as inhibitors of NF-kB
WO2007098169A1 (en) * 2006-02-21 2007-08-30 Amgen Inc. Cinnoline derivatives as phosphodiesterase 10 inhibitors
JP5304785B2 (ja) * 2008-06-23 2013-10-02 アステラス製薬株式会社 スルホンアミド化合物又はその塩
EP2677865A4 (en) * 2011-02-23 2015-04-22 Icahn School Med Mount Sinai BROMODOMAIN INHIBITORS AS MODULATORS OF GENE EXPRESSION
DK3300500T3 (da) 2015-05-20 2020-05-18 Amgen Inc Triazolagonister af apj-receptoren
CN108602775B (zh) 2016-01-14 2022-04-29 贝思以色列女会吏医学中心公司 肥大细胞调节剂及其用途
WO2017192485A1 (en) 2016-05-03 2017-11-09 Amgen Inc. Heterocyclic triazole compounds as agonists of the apj receptor
WO2018093579A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Triazole phenyl compounds as agonists of the apj receptor
US11020395B2 (en) 2016-11-16 2021-06-01 Amgen Inc. Cycloalkyl substituted triazole compounds as agonists of the APJ receptor
EP3541792B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole furan compounds as agonists of the apj receptor
WO2018093576A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Alkyl substituted triazole compounds as agonists of the apj receptor
US11046680B1 (en) 2016-11-16 2021-06-29 Amgen Inc. Heteroaryl-substituted triazoles as APJ receptor agonists
EP3541803B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole pyridyl compounds as agonists of the apj receptor
US11149040B2 (en) 2017-11-03 2021-10-19 Amgen Inc. Fused triazole agonists of the APJ receptor
WO2019213006A1 (en) 2018-05-01 2019-11-07 Amgen Inc. Substituted pyrimidinones as agonists of the apj receptor
CN111056978B (zh) * 2019-12-13 2021-01-19 西安交通大学 一种磺酰胺类化合物及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2396145A (en) 1940-12-14 1946-03-05 Pharmscia Ab Heterocyclic sulphonamido azo compounds
BE791889A (fr) * 1971-11-26 1973-05-24 Pharmacia Ab Nouveaux derives de la pyridine
AU567140B2 (en) * 1984-01-06 1987-11-12 Shionogi & Co., Ltd. Sulphonamido-benzamide derivatives
US4663334A (en) * 1985-12-11 1987-05-05 Mcneilab, Inc. Heteroaromatic acetylenes useful as antihypertensive agents
US4897397A (en) * 1988-12-16 1990-01-30 Schering Corporation Aryl-alkynoic, alkenoic or alkanoic compounds and compositions useful as antiallergy and anti-inflammatory agents

Also Published As

Publication number Publication date
ZA928864B (en) 1993-05-13
PT101068A (pt) 1994-02-28
WO1993010094A1 (en) 1993-05-27
NZ244998A (en) 1995-09-26
KR100253748B1 (ko) 2000-05-01
UA42869C2 (uk) 2001-11-15
IL103665A0 (en) 1993-04-04
LV10246A (lv) 1994-10-20
CA2123697A1 (en) 1993-05-27
NO300805B1 (no) 1997-07-28
TW304944B (lt) 1997-05-11
EP0613468A1 (en) 1994-09-07
EP0613468B1 (en) 2000-07-12
FI942289L (fi) 1994-05-17
US5556855A (en) 1996-09-17
MX9206647A (es) 1993-05-01
NO941799L (lt) 1994-06-22
JPH07501330A (ja) 1995-02-09
HU9401391D0 (en) 1994-08-29
SE9103397D0 (sv) 1991-11-18
FI942289A0 (fi) 1994-05-17
PT101068B (pt) 1999-08-31
SK54794A3 (en) 1995-02-08
GR3034585T3 (en) 2001-01-31
DE69231252T2 (de) 2001-03-01
HU211163A9 (en) 1995-10-30
CA2123697C (en) 2003-12-09
DK0613468T3 (da) 2000-10-23
JP3259915B2 (ja) 2002-02-25
HU221476B (en) 2002-10-28
RU2124501C1 (ru) 1999-01-10
LTIP229A (en) 1994-09-25
NO941799D0 (no) 1994-05-13
IL103665A (en) 1997-08-14
AU2958992A (en) 1993-06-15
HUT69723A (en) 1995-09-28
LV10246B (en) 1995-04-20
SK282080B6 (sk) 2001-10-08
MY130169A (en) 2007-06-29
US5403930A (en) 1995-04-04
ATE194597T1 (de) 2000-07-15
AU668528B2 (en) 1996-05-09
ES2149780T3 (es) 2000-11-16
DE69231252D1 (de) 2000-08-17
US5302718A (en) 1994-04-12
FI106857B (fi) 2001-04-30
LT3182B (en) 1995-03-27

Similar Documents

Publication Publication Date Title
EE03026B1 (et) Asendatud salitsüülhapped, meetod nende valmistamiseks ja nende kasutamine
RU94028109A (ru) Новые замещенные салициловые кислоты, способ их получения
DK0638071T3 (da) Heterocykliske carboxylsyrederivater, der bindes til retenoidreceptorer (RAR)
DK0934276T3 (da) Anthranilinsyrederivater som multiresistensmodulatorer
FI940414A0 (fi) Kinoliini- tai kinatsoliinijohdannaiset, niiden valmistus ja käyttö
DK0715623T3 (da) Blodpladeaggregationsinhibitorer
ATE157088T1 (de) Neue chinolon- und naphthyridoncarbonsäurederivate
NO307688B1 (no) Anvendelse av terfenadinderivater som antihistaminmidler i et farmasøytisk preparat
DK0659193T3 (da) Blodpladeaggregationsinhibitorer
ES2134313T3 (es) Utilizacion de derivados de pregnano para el tratamiento de tumores.
UA41350C2 (uk) Похідна морфоліну або її фармацевтично прийнятна сіль та фармацевтична композиція на її основі
DE69413831D1 (de) Phenoxyphenylcyclopentenyl-hydroxyharnstoffe
DE59703968D1 (de) Neue polycyclische phthalazinderivate und ihre verwendung
ES2116528T3 (es) Nuevo compuesto, la leustroducsina h, su preparacion y su utilizacion terapeutica.
AR014977A1 (es) Procedimiento de preparacion de la 3-hidroximetilquinuclidina, un compuesto intermediario de sintesis para dicho procedimiento y procedimiento de preparacion de mequitazina
UY25065A1 (es) Compuestos piridilicos que tienen actividad antihistaminica

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

MM4A Lapsed by not paying the annual fees

Effective date: 20061102